Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Symptomatic abnormal vessel wall reaction after implantation of the first generation sirolimus-eluting stent: a case series.

Mostafa AE, Richardt G, Abdel-Wahab M.

Cardiovasc Revasc Med. 2012 May-Jun;13(3):196-200. doi: 10.1016/j.carrev.2012.02.008.

PMID:
22652316
2.

First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.

3.

Acute myocardial infarction related to very late sirolimus-eluting stent thrombosis 6 months after discontinuation of dual antiplatelet therapy.

Balbi M, Fedele M, Bezante GP, Brunelli C, Barsotti A.

J Cardiovasc Med (Hagerstown). 2011 Nov;12(11):839-42. doi: 10.2459/JCM.0b013e328337d7e7. No abstract available.

PMID:
20216229
4.

Simultaneous very late stent thrombosis in multiple coronary arteries.

Narasimhan S, Krim NR, Silverman G, Monrad ES.

Tex Heart Inst J. 2012;39(5):630-4.

5.

Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes.

Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, Jiang T, Li Z, Zhang H, Li H, Qiu J, Liu Y, Li Y, Chen X, Gao R; CREATE (Multi-Center Registry of Excel Biodegradable Polymer Drug-Eluting Stents) Investigators.

JACC Cardiovasc Interv. 2009 Apr;2(4):303-9. doi: 10.1016/j.jcin.2008.12.013.

6.

Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.

Costa JR Jr, Abizaid A, Costa R, Feres F, Tanajura LF, Abizaid A, Mattos LA, Staico R, Siqueira D, Sousa AG, Bonan R, Sousa JE.

JACC Cardiovasc Interv. 2008 Oct;1(5):545-51. doi: 10.1016/j.jcin.2008.07.003.

7.

Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.

Hahn JY, Song YB, Choi JH, Choi SH, Lee SY, Park HS, Hur SH, Lee S, Han KR, Rha SW, Cho BR, Park JS, Yoon J, Lim DS, Lee SH, Gwon HC; DATE Registry Investigators.

Circ J. 2010 Nov;74(11):2314-21. Epub 2010 Oct 2.

8.

Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review.

Al-Dehneh A, Virk H, Alkhouri Y, Hamdan A, Bikkina M.

Tex Heart Inst J. 2010;37(3):343-6. Review.

9.

Sirolimus-eluting stents versus bare-metal stents in routine clinical use: a nonrandomized comparison.

Munir M, Aliota J, Ahmed A, Mohammed A, Lee VV, Elayda MA, Wilson JM.

Tex Heart Inst J. 2011;38(5):508-15.

10.

2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice.

Klauss V, Serruys PW, Pilgrim T, Buszman P, Linke A, Ischinger T, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, van Geuns RJ, van Es GA, Kalesan B, Wenaweser P, Jüni P, Windecker S.

JACC Cardiovasc Interv. 2011 Aug;4(8):887-95. doi: 10.1016/j.jcin.2011.03.017.

11.

Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation.

Ko YG, Kim DM, Cho JM, Choi SY, Yoon JH, Kim JS, Kim BK, Choi D, Jang Y, Hong MK.

Int J Cardiovasc Imaging. 2012 Apr;28(4):715-23. doi: 10.1007/s10554-011-9905-3. Epub 2011 Jun 8.

PMID:
21656060
13.

Long-term clinical and angiographic outcomes after implantation of sirolimus-eluting stents with a "modified mini-crush" technique in coronary bifurcation lesions.

Yang HM, Tahk SJ, Woo SI, Lim HS, Choi BJ, Choi SY, Yoon MH, Park JS, Zheng M, Hwang GS, Kang SJ, Shin JH.

Catheter Cardiovasc Interv. 2009 Jul 1;74(1):76-84. doi: 10.1002/ccd.22020.

PMID:
19360861
14.

Long-term outcomes of sirolimus-eluting stents vs. paclitaxel-eluting stents in unprotected left main coronary artery bifurcation lesions.

Song PS, Ryu DR, Song YB, Hahn JY, Choi JH, Choi SH, Lee SH, Hong KP, Park JE, Gwon HC.

Clin Cardiol. 2011 Jun;34(6):378-83. doi: 10.1002/clc.20887. Epub 2011 Apr 27.

15.

Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents.

Claessen BE, Mehran R, Mintz GS, Weisz G, Leon MB, Dogan O, de Ribamar Costa J Jr, Stone GW, Apostolidou I, Morales A, Chantziara V, Syros G, Sanidas E, Xu K, Tijssen JG, Henriques JP, Piek JJ, Moses JW, Maehara A, Dangas GD.

JACC Cardiovasc Interv. 2011 Sep;4(9):974-81. doi: 10.1016/j.jcin.2011.07.005. Erratum in: JACC Cardiovasc Interv. 2011 Nov;4(11):1255.

17.

Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.

Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Stanco G, Rosato G, Suryapranata H, De Luca G.

JACC Cardiovasc Interv. 2014 Aug;7(8):849-56. doi: 10.1016/j.jcin.2014.02.016.

18.

Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.

Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE; ENDEAVOR IV Investigators.

JACC Cardiovasc Interv. 2010 Oct;3(10):1043-50. doi: 10.1016/j.jcin.2010.07.008.

19.

Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.

Ahn JM, Park DW, Kim YH, Song H, Cho YR, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Han S, Lee SY, Lee BK, Cho JH, Yang TH, Lee NH, Yang JY, Park JS, Shin WY, Kim MH, Bae JH, Kim MK, Yoon J, Park SJ.

Circ Cardiovasc Interv. 2012 Oct;5(5):633-40. doi: 10.1161/CIRCINTERVENTIONS.111.965673. Epub 2012 Oct 9.

20.

Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.

Chacko R, Mulhearn M, Novack V, Novack L, Mauri L, Cohen SA, Moses J, Leon MB, Cutlip DE.

JACC Cardiovasc Interv. 2009 Jun;2(6):498-503. doi: 10.1016/j.jcin.2009.03.013.

Supplemental Content

Support Center